

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K/A

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

June 29, 2012

ALBANY INTERNATIONAL CORP.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction
of incorporation)

1-10026

(Commission
File Number)

14-0462060

(I.R.S. Employer
Identification No.)

216 Airport Drive, Rochester, NH

(Address of principal executive offices)

03867

(Zip Code)

Registrant's telephone number, including area code (518) 445-2200

None

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13a-4(c))
-

TABLE OF CONTENTS

Item 9.01 Financial Statements and Exhibits

On July 3, 2012, Albany International Corp. (the “Company”) filed a current report on Form 8-K reporting the completed sale of the Company’s global Primaloft® Products business to PrimaLoft, Inc. on June 29. The Company will account for the sale of this business as a Discontinued Operation in its future quarterly and annual reports.

Basis of presentation:

The unaudited pro forma financial information required pursuant to Item 9.01(b) and Article 11 of Regulation S-X as the result of such sale is reflected in the financial information set forth in columns described as “Reclassify Primaloft to Discontinued Operations” in the Exhibits filed with this Form 8-K. The financial information in these Exhibits reflects not only the effect of the completed transaction, but also the effects of a change in segment reporting and the sale of the Company’s Albany Door Systems business, both as previously reported.

During the periods presented, the Primaloft® Products business was as an operating segment within the Company. As such, the Company did not maintain separate, stand-alone financial statements for that business. Accordingly, the financial information of the Primaloft® Products business has been prepared from the historical accounting records of the Company and does not purport to reflect a balance sheet and income statement that would have resulted in the Primaloft® Products had been operated as a separate stand-alone company. The unaudited pro forma financial statements should be read together with the Company’s Annual Report on Form 10-K for the year ended December 31, 2011 and its quarterly report for the three months ended March 31, 2012.

Effective with the first quarter of 2012, we merged our Paper Machine Clothing (PMC) and Engineered Fabrics (EF) business segments. The combined segment is called Machine Clothing (MC). The change was made to better align financial reporting with our organizational structure. In the fourth quarter of 2011, we announced the sale of our Albany Door Systems business (ADS) and, beginning with the fourth quarter of 2011, we presented the results of that business as a discontinued operation. The attached schedules also reflect the reclassification of amounts previously reported in the Income Statement as Earnings from Associated Companies into Other income/expense.

Exhibits

99.1	Effect of changes on amounts previously reported for Q1 2011.
99.2	Effect of changes on amounts previously reported for Q1 2012.
99.3	Effect of changes on amounts previously reported for full year 2011.
99.4	Effect of changes on amounts previously reported for full year 2010.
99.5	Effect of changes on amounts previously reported for full year 2009.
99.6	Effect of changes on Income Statement for Q1 2011.
99.7	Effect of changes on Income Statement for Q1 2012.
99.8	Effect of changes on Income Statement for full year 2011.
99.9	Effect of changes on Income Statement for full year 2010.
99.10	Effect of changes on Income Statement for full year 2009.
99.11	Effect of changes on Balance Sheets for March 31, 2012 and December 31, 2011.

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ALBANY INTERNATIONAL CORP.

By: /s/ John B. Cozzolino

Name: John B. Cozzolino
Title: Chief Financial Officer and Treasurer
(Principal Financial Officer)

Date: July 19, 2012

EXHIBIT INDEX

Exhibit No.	Description
99.1	Effect of changes on amounts previously reported for Q1 2011.
99.2	Effect of changes on amounts previously reported for Q1 2012.
99.3	Effect of changes on amounts previously reported for full year 2011.
99.4	Effect of changes on amounts previously reported for full year 2010.
99.5	Effect of changes on amounts previously reported for full year 2009.
99.6	Effect of changes on Income Statement for Q1 2011.
99.7	Effect of changes on Income Statement for Q1 2012.
99.8	Effect of changes on Income Statement for full year 2011.
99.9	Effect of changes on Income Statement for full year 2010.
99.10	Effect of changes on Income Statement for full year 2009.
99.11	Effect of changes on Balance Sheets for March 31, 2012 and December 31, 2011.

99.1 Effect of changes on amounts previously reported for Q1 2011.

	USD 000's	Q1 2011 As reported	Reclassify Primaloft to Discontinued	Q1 2011 as restated
Net sales	Machine Clothing	\$ 188,482	\$ -	\$ 188,482
	Composites	11,472		11,472
	Primaloft	6,768	(6,768)	-
	Total	\$ 206,722	\$ (6,768)	\$ 199,954
Gross margin	Machine Clothing	\$ 86,537	\$ -	\$ 86,537
	Composites	(19)		(19)
	Primaloft	3,657	(3,657)	-
	Non Segment	(1,330)		(1,330)
Total	\$ 88,845	\$ (3,657)	\$ 85,188	
Selling, technical general and research expenses	Machine Clothing	\$ 36,233	\$ -	\$ 36,233
	Composites	1,011		1,011
	Primaloft	1,746	(1,746)	-
	Research	7,165		7,165
	Non Segment	15,675	(4)	15,671
Total	\$ 61,830	\$ (1,750)	\$ 60,080	
Restructuring included in segment operating income	Machine Clothing	\$ 33	\$ -	\$ 33
	Composites	13		13
	Primaloft	-	-	-
	Research	-		-
	Non Segment	(12)		(12)
Total	\$ 34	\$ -	\$ 34	
Operating income	Machine Clothing	\$ 50,271	\$ -	\$ 50,271
	Composites	(1,043)		(1,043)
	Primaloft	1,911	(1,911)	-
	Research	(7,165)		(7,165)
	Non Segment	(16,993)	4	(16,989)
Total	\$ 26,981	\$ (1,907)	\$ 25,074	

99.2 Effect of changes on amounts previously reported for Q1 2012.

	USD 000's	Q1 2012 As reported	Reclassify Primaloft to Discontinued	Q1 2012 as restated
Net sales	Machine Clothing	\$ 164,288	\$ -	\$ 164,288
	Composites	15,789		15,789
	Primaloft	8,476	(8,476)	-
	Total	\$ 188,553	\$ (8,476)	\$ 180,077
Gross margin	Machine Clothing	\$ 67,998	\$ -	\$ 67,998
	Composites	1,393		1,393
	Primaloft	3,548	(3,548)	-
	Non Segment	(1,105)		(1,105)
Total	\$ 71,834	\$ (3,548)	\$ 68,286	
Selling, technical general and research expenses	Machine Clothing	\$ 36,480	\$ -	\$ 36,480
	Composites	1,364		1,364
	Primaloft	1,992	(1,992)	-
	Research	6,065		6,065
Non Segment	15,853		15,853	
Total	\$ 61,754	\$ (1,992)	\$ 59,762	
Pension settlement charge	Non Segment	\$ 9,175	\$ -	\$ 9,175
Restructuring included in segment operating income	Machine Clothing	\$ 673	\$ -	\$ 673
	Composites			-
	Primaloft	-	-	-
	Research	-		-
Non Segment	(415)		(415)	
Total	\$ 258	\$ -	\$ 258	
Operating income	Machine Clothing	\$ 30,845	\$ -	\$ 30,845
	Composites	29		29
	Primaloft	1,556	(1,556)	-
	Research	(6,065)		(6,065)
Non Segment	(25,718)		(25,718)	
Total	\$ 647	\$ (1,556)	\$ (909)	

99.3 Effect of changes on amounts previously reported for full year 2011.

	USD 000's	Fiscal year 2011 As reported	Merge PMC and EF	Reclassify Primaloft to Discontinued	Fiscal year 2011 in 2012 format
Net sales	PMC	\$ 657,569	\$ (657,569)		\$ -
	Machine Clothing	-	739,211		739,211
	EF	81,642	(81,642)		-
	Composites	48,076			48,076
	Primaloft	27,409		(27,409)	-
	Total	\$ 814,696	\$ -	\$ (27,409)	\$ 787,287
Gross margin	PMC	\$ 288,456	\$ (288,456)		\$ -
	Machine Clothing	-	317,984		317,984
	EF	29,528	(29,528)		-
	Composites	507			507
	Primaloft	14,795		(14,795)	-
	Non Segment	(4,325)			(4,325)
Total	\$ 328,961	\$ -	\$ (14,795)	\$ 314,166	
Selling, technical general and research expenses	PMC	\$ 119,668	\$ (119,668)	\$ -	\$ -
	Machine Clothing	-	135,546		135,546
	EF	15,878	(15,878)		-
	Composites	4,654			4,654
	Primaloft	6,255		(6,255)	-
	Research	29,007			29,007
Non Segment	61,109		(74)	61,035	
Total	\$ 236,571	\$ -	\$ (6,329)	\$ 230,242	
Restructuring included in segment	PMC	\$ 3,260	\$ (3,260)		\$ -
	Machine Clothing	-	5,680		5,680
	EF	2,420	(2,420)		-
	Composites	57			57
	Primaloft	-		-	-
	Research	-			-
Non Segment	3,580			3,580	
Total	\$ 9,317	\$ -	\$ -	\$ 9,317	
Operating income	PMC	\$ 165,528	\$ (165,528)	\$ -	\$ -
	Machine Clothing	-	176,758	-	176,758
	EF	11,230	(11,230)	-	-
	Composites	(4,204)	-	-	(4,204)
	Primaloft	8,540	-	(8,540)	-
	Research	(29,007)	-	-	(29,007)
Non Segment	(69,014)	-	74	(68,940)	
Total	\$ 83,073	\$ -	\$ (8,466)	\$ 74,607	

99.4 Effect of changes on amounts previously reported for full year 2010.

	USD 000's	2010 As reported	Merge PMC and EF	Reclassify Primaloft to Discontinued	Full year 2010 in 2012 format
Net sales	PMC	\$ 623,555	\$ (623,555)		\$ -
	Machine Clothing	-	701,020		701,020
	EF	77,465	(77,465)		-
	Composites	41,867			41,867
	Primaloft	22,882		(22,882)	-
	Total	\$ 765,769	\$ -	\$ (22,882)	\$ 742,887
Gross margin	PMC	\$ 265,111	\$ (265,111)		\$ -
	Machine Clothing	-	290,426		290,426
	EF	25,315	(25,315)		-
	Composites	(2,608)			(2,608)
	Primaloft	12,790		(12,790)	-
	Non Segment	(5,845)			(5,845)
Total	\$ 294,763	\$ -	\$ (12,790)	\$ 281,973	
Selling, technical general and research expenses	PMC	\$ 104,845	\$ (104,845)	\$ -	\$ -
	Machine Clothing	-	120,002		120,002
	EF	15,157	(15,157)		-
	Composites	5,638			5,638
	Primaloft	6,180		(6,180)	-
	Research	26,064			26,064
	Non Segment	61,847		(34)	61,813
Total	\$ 219,731	\$ -	\$ (6,214)	\$ 213,517	
Restructuring included in segment	PMC	\$ 3,705	\$ (3,705)		\$ -
	Machine Clothing	-	4,762		4,762
	EF	1,057	(1,057)		-
	Composites	930			930
	Primaloft	-		-	-
	Research	-			-
Non Segment	(1,945)			(1,945)	
Total	\$ 3,747	\$ -	\$ -	\$ 3,747	
Operating income	PMC	\$ 156,561	\$ (156,561)	\$ -	\$ -
	Machine Clothing	-	165,662	-	165,662
	EF	9,101	(9,101)	-	-
	Composites	(9,176)	-	-	(9,176)
	Primaloft	6,610	-	(6,610)	-
	Research	(26,064)	-	-	(26,064)
	Non Segment	(65,747)	-	34	(65,713)
Total	\$ 71,285	\$ -	\$ (6,576)	\$ 64,709	

99.5 Effect of changes on amounts previously reported for full year 2009.

	USD 000's	2009 As reported	Merge PMC and EF	Reclassify Primaloft to Discontinued	Full year 2009 in 2012 format
Net sales	PMC	\$ 609,897	\$ (609,897)		\$ -
	Machine Clothing	-	684,805		684,805
	EF	74,908	(74,908)		-
	Composites	33,824			33,824
	Primaloft	18,992		(18,992)	-
	Total	\$ 737,621	\$ -	\$ (18,992)	\$ 718,629
Gross margin	PMC	\$ 228,301	\$ (228,301)		\$ -
	Machine Clothing	-	251,634		251,634
	EF	23,333	(23,333)		-
	Composites	(2,487)			(2,487)
	Primaloft	8,853		(8,853)	-
	Non Segment	(4,714)			(4,714)
Total	\$ 253,286	\$ -	\$ (8,853)	\$ 244,433	
Selling, technical general and research expenses	PMC	\$ 118,736	\$ (118,736)	\$ -	\$ -
	Machine Clothing	-	134,711		134,711
	EF	15,975	(15,975)		-
	Composites	3,875			3,875
	Primaloft	5,103		(5,103)	-
	Research	23,849			23,849
	Non Segment	53,700		(95)	53,605
Total	\$ 221,238	\$ -	\$ (5,198)	\$ 216,040	
Restructuring included in segment	PMC	\$ 66,941	\$ (66,941)		\$ -
	Machine Clothing	-	71,252		71,252
	EF	4,311	(4,311)		-
	Composites	291			291
	Primaloft	61		(61)	-
	Research	-			-
	Non Segment	(3,430)			(3,430)
Total	\$ 68,174	\$ -	\$ (61)	\$ 68,113	
Operating income	PMC	\$ 42,624	\$ (42,624)	\$ -	\$ -
	Machine Clothing	-	45,671	-	45,671
	EF	3,047	(3,047)	-	-
	Composites	(6,653)	-	-	(6,653)
	Primaloft	3,689	-	(3,689)	-
	Research	(23,849)	-	-	(23,849)
	Non Segment	(54,984)	-	95	(54,889)
Total	\$ (36,126)	\$ -	\$ (3,594)	\$ (39,720)	

99.6 Effect of changes on Income Statement for Q1 2011 (000's, except for per share amounts).

	As reported Three months ended March 31, 2011	Reclassify Primaloft to discontinued operations	Q1 2011 reported in 2012 format
Net sales	\$206,722	(\$6,768)	\$199,954
Cost of goods sold	117,877	(3,111)	114,766
Gross profit	88,845	(3,657)	85,188
Selling, general, and administrative expenses	47,476	(1,509)	45,967
Technical, product engineering, and research expenses	14,354	(241)	14,113
Restructuring and other, net	34	-	34
Pension settlement expense	-	-	-
Operating income	26,981	(1,907)	25,074
Interest expense, net	4,776	-	4,776
Other expense, net	4,813	-	4,813
Income before income taxes	17,392	(1,907)	15,485
Income tax expense/(benefit)	3,988	(721)	3,267
Income from continuing operations before earnings of associated companies	13,404	(1,186)	12,218
Equity in losses from associated companies	-	-	-
Income from continuing operations	13,404	(1,186)	12,218
Income from operations of discontinued business	4,650	1,907	6,557
Gain on sale of discontinued business	-	-	0
Income tax expense on discontinued operations	1,321	721	2,042
Income from discontinued operations	3,329	1,186	4,515
Net income	\$16,733	\$0	\$16,733
Earnings per share - Basic			
(Loss)/income from continuing operations	\$0.43	(\$0.04)	\$0.39
Discontinued operations	0.11	0.04	0.15
Net (loss)/income	\$0.54	\$0.00	\$0.54
Earnings per share - Diluted			
(Loss)/income from continuing operations	\$0.43	(\$0.04)	\$0.39
Discontinued operations	0.10	0.04	0.14
Net (loss)/income	\$0.53	\$0.00	\$0.53
Shares used in computing earnings per share:			
Basic	31,223	31,223	31,223
Diluted	31,384	31,384	31,384

99.7 Effect of changes on Income Statement for Q1 2012 (000's, except for per share amounts).

	As reported Three months ended March 31, 2012	Reclassify Primaloft to discontinued operations	Q1 2012 reported in current format
Net sales	\$188,553	(\$8,476)	\$180,077
Cost of goods sold	116,719	(4,928)	111,791
Gross profit	71,834	(3,548)	68,286
Selling, general, and administrative expenses	48,815	(1,792)	47,023
Technical, product engineering, and research expenses	12,939	(200)	12,739
Restructuring and other, net	258	-	258
Pension settlement expense	9,175	-	9,175
Operating income	647	(1,556)	(909)
Interest expense, net	4,644	-	4,644
Other expense, net	4,548	-	4,548
Income before income taxes	(8,545)	(1,556)	(10,101)
Income tax expense/(benefit)	(9,379)	(593)	(9,972)
Income from continuing operations	834	(963)	(129)
Income from operations of discontinued business	460	1,556	2,016
Gain on sale of discontinued business	57,968	-	57,968
Income tax expense on discontinued operations	12,221	593	12,814
Income from discontinued operations	46,207	963	47,170
Net income	\$47,041	\$ -	\$47,041
Earnings per share - Basic			
(Loss)/income from continuing operations	\$0.03		\$0.00
Discontinued operations	\$1.47		\$1.50
Net (loss)/income	\$1.50		\$1.50
Earnings per share - Diluted			
(Loss)/income from continuing operations	\$0.03		\$0.00
Discontinued operations	\$1.46		\$1.49
Net (loss)/income	\$1.49		\$1.49
Shares used in computing earnings per share:			
Basic	31,309		31,309
Diluted	31,533		31,533

99.8 Effect of changes on Income Statement for full year 2011 (000's, except for per share amounts).

	As reported Year ended December 31, 2011	Reclassify Primaloft to discontinued operations	Other reclassifications	Year ended December 31, 2011 reported in 2012 format
Net sales	\$814,696	(\$27,409)		\$787,287
Cost of goods sold	485,735	(12,614)		473,121
Gross profit	328,961	(14,795)	-	314,166
Selling, general, and administrative expenses	179,804	(5,409)		174,395
Technical, product engineering, and research expenses	56,767	(921)		55,846
Restructuring and other, net	9,317	-		9,317
Operating income	83,073	(8,465)	0	74,608
Interest expense, net	18,121	-		18,121
Other (income)/expense, net	2,720	-	(81)	2,639
Income before income taxes	62,232	(8,465)	81	53,848
Income tax expense/(benefit)	35,779	(3,197)		32,582
Income from continuing operations before earnings of associated companies	26,453	(5,268)	81	21,266
Equity in (earnings)/losses from associated companies	(81)	-	81	-
Income from continuing operations	26,534	(5,268)	-	21,266
Income from operations of discontinued business	15,636	8,465		24,101
Gain on sale of discontinued business	-	-		-
Income tax expense on discontinued operations	7,232	3,197		10,429
Income from discontinued operations	8,404	5,268		13,672
Net income	\$34,938	\$ -	\$ -	\$34,938
Earnings per share - Basic				
(Loss)/income from continuing operations	\$0.85			\$0.68
Discontinued operations	0.27			0.44
Net (loss)/income	\$1.12			\$1.12
Earnings per share - Diluted				
(Loss)/income from continuing operations	\$0.84			\$0.67
Discontinued operations	0.27			\$0.44
Net (loss)/income	\$1.11			\$1.11
Shares used in computing earnings per share:				
Basic	31,262			31,262
Diluted	31,510			31,510

99.9 Effect of changes on Income Statement for full year 2010 (000's, except for per share amounts).

	As reported Year ended December 31, 2010	Reclassify Primaloft to discontinued operations	Other reclassifications	Year ended December 31, 2010 reported in 2012 format
Net sales	\$765,769	(\$22,882)		\$742,887
Cost of goods sold	471,006	(10,092)		460,914
Gross profit	294,763	(12,790)	-	281,973
Selling, general, and administrative expenses	165,528	(5,402)		160,126
Technical, product engineering, and research expenses	54,203	(812)		53,391
Restructuring and other, net	3,747	-		3,747
Operating income	71,285	(6,576)	0	64,709
Interest expense, net	17,240	-		17,240
Other (income)/expense, net	(884)	-	(92)	(976)
Income before income taxes	54,929	(6,576)	92	48,445
Income tax expense/(benefit)	23,545	(2,523)		21,022
Income from continuing operations before earnings of associated companies	31,384	(4,053)	92	27,423
Equity in (earnings)/losses from associated companies	(92)	-	92	-
Income from continuing operations	31,476	(4,053)	-	27,423
Income from operations of discontinued business	9,497	6,576		16,073
Gain on sale of discontinued business	-	-		-
Income tax expense on discontinued operations	3,337	2,523		5,860
Income from discontinued operations	6,160	4,053		10,213
Net income	\$37,636	\$ -	\$ -	\$37,636
Earnings per share - Basic				
(Loss)/income from continuing operations	\$1.01			\$0.88
Discontinued operations	0.20			0.33
Net (loss)/income	\$1.21			\$1.21
Earnings per share - Diluted				
(Loss)/income from continuing operations	\$1.01			\$0.88
Discontinued operations	0.20			\$0.33
Net (loss)/income	\$1.21			\$1.21
Shares used in computing earnings per share:				
Basic	31,072			31,072
Diluted	31,209			31,209

99.10 Effect of changes on Income Statement for full year 2009 (000's, except for per share amounts).

	As reported Year ended December 31, 2009	Reclassify Primaloft to discontinued operations	Other reclassifications	Year ended December 31, 2009 reported in 2012 format
Net sales	\$737,621	(\$18,992)		\$718,629
Cost of goods sold	484,335	(10,139)		474,196
Gross profit	253,286	(8,853)	-	244,433
Selling, general, and administrative expenses	168,709	(4,717)		163,992
Technical, product engineering, and research expenses	52,529	(481)		52,048
Restructuring and other, net	68,174	(61)		68,113
Operating income/(loss)	(36,126)	(3,594)	0	(39,720)
Interest expense, net	20,627	-		20,627
Other (income)/expense, net	(49,700)	-	(32)	(49,732)
Income before income taxes	(7,053)	(3,594)	32	(10,615)
Income tax expense/(benefit)	14,440	(1,523)		12,917
Income from continuing operations before earnings of associated companies	(21,493)	(2,071)	32	(23,532)
Equity in (earnings)/losses from associated companies	(32)	-	32	-
Income from continuing operations	(21,461)	(2,071)	-	(23,532)
Income from operations of discontinued business	(12,061)	3,594		(8,467)
Gain on sale of discontinued business	-	-		-
Income tax expense on discontinued operations	(64)	1,523		1,459
Income from discontinued operations	(11,997)	2,071		(9,926)
Net income	(\$33,458)	\$ -	\$ -	(\$33,458)
Earnings per share - Basic				
(Loss)/income from continuing operations	(\$0.70)			(\$0.77)
Discontinued operations	(0.39)			(0.32)
Net (loss)/income	(\$1.09)			(\$1.09)
Earnings per share - Diluted				
(Loss)/income from continuing operations	(\$0.70)			(\$0.77)
Discontinued operations	(0.39)			(0.32)
Net (loss)/income	(\$1.09)			(\$1.09)
Shares used in computing earnings per share:				
Basic	30,612			30,612
Diluted	30,612			30,612

	March 31, 2012 As previously reported	March 31, 2012 Reclassify Primaloft to Discontinued	March 31, 2012 Updated Q2 2012	December 31, 2011 As previously reported	December 31, 2011 Reclassify Primaloft to Discontinued	December 31, 2011 Updated Q2 2012
ASSETS						
Cash and cash equivalents	\$140,925	\$ -	\$140,925	\$118,909	\$ -	\$118,909
Accounts receivable, net	152,126	(2,098)	150,028	148,849	(1,338)	147,511
Inventories	138,299	(3,685)	134,614	133,649	(3,846)	129,803
Income taxes receivable and deferred	23,724	-	23,724	30,010	-	30,010
Prepaid expenses and other current assets	13,464	(102)	13,362	13,409	(60)	13,349
Current assets of discontinued operations	2,596	5,885	8,481	62,107	5,244	67,351
Total current assets	471,134	-	471,134	506,933	-	506,933
Property, plant and equipment, net	434,266	(444)	433,822	439,516	(563)	438,953
Intangibles	1,021	-	1,021	1,079	-	1,079
Goodwill	77,148	-	77,148	75,469	-	75,469
Deferred taxes	127,362	-	127,362	134,644	-	134,644
Other assets	36,448	-	36,448	22,504	-	22,504
Noncurrent assets of discontinued operations	279	444	723	50,783	563	51,346
Total assets	\$1,147,658	-	\$1,147,658	\$1,230,928	-	\$1,230,928
LIABILITIES AND SHAREHOLDERS' EQUITY						
Notes and loans payable	\$193	\$ -	\$193	\$424	\$ -	\$424
Accounts payable	37,732	(2,571)	35,161	33,663	(955)	32,708
Accrued liabilities	104,989	(1,133)	103,856	105,649	(545)	105,104
Current maturities of long-term debt	30,145	-	30,145	1,263	-	1,263
Income taxes payable and deferred	7,010	-	7,010	8,766	-	8,766
Current liabilities of discontinued operations	2,675	3,704	6,379	20,946	1,500	22,446
Total current liabilities	182,744	-	182,744	170,711	-	170,711
Long-term debt	296,636	-	296,636	373,125	-	373,125
Other noncurrent liabilities	127,993	(54)	127,939	185,648	(52)	185,596
Deferred taxes and other credits	61,066	-	61,066	71,529	-	71,529
Noncurrent liabilities of discontinued operations	-	54	54	14,065	52	14,117
Total liabilities	668,439	-	668,439	815,078	-	815,078
Commitments and Contingencies	-	-	-	-	-	-
SHAREHOLDERS' EQUITY						
Preferred stock, par value \$5.00 per share; authorized 2,000,000 shares; none issued	-	-	-	-	-	-
Class A Common Stock, par value \$.001 per share; authorized 100,000,000 shares; issued 36,585,004 in 2012 and 36,540,842 in 2011	37	-	37	37	-	37
Class B Common Stock, par value \$.001 per share; authorized 25,000,000 shares; issued and outstanding 3,236,098 in 2012 and 2011	3	-	3	3	-	3
Additional paid in capital	391,611	-	391,611	391,495	-	391,495
Retained earnings	465,016	-	465,016	422,044	-	422,044
Accumulated items of other comprehensive income:						
Translation adjustments	(6,244)	-	(6,244)	(19,111)	-	(19,111)
Pension and post retirement liability adjustments	(110,480)	-	(110,480)	(118,104)	-	(118,104)
Derivative valuation adjustment	(2,804)	-	(2,804)	(2,594)	-	(2,594)
Treasury stock (Class A), at cost 8,479,487 shares in 2012 and 2011	(257,920)	-	(257,920)	(257,920)	-	(257,920)
Total shareholders' equity	479,219	-	479,219	415,850	-	415,850
Total liabilities and shareholders' equity	\$1,147,658	\$ -	\$1,147,658	\$1,230,928	\$ -	\$1,230,928